STOCK TITAN

[Form 4] MACOM Technology Solutions Holdings, Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview: Clover Health Investments (CLOV) reported insider activity by Jamie L. Reynoso, listed as “CEO, Medicare Advantage.” On 30 June 2025 Ms. Reynoso earned 217,523 Class A shares through the final tranche of a March 16 2023 performance-based RSU award. To satisfy withholding taxes, the company automatically sold 85,596 shares at $2.79 per share. After the automatic sale, Ms. Reynoso’s direct ownership stands at 3,328,328 Class A shares, up roughly 132 k shares versus the prior balance.

  • Nature of transaction: “A” code denotes acquisition from equity award; “F” code denotes shares withheld for taxes—neither represents an open-market trade.
  • Cost basis: RSUs were settled at no cash cost to the insider; only the tax-withholding sale carries a market price.
  • Alignment impact: The executive retains a sizable equity stake (≈3.3 million shares), reinforcing incentive alignment, but no new cash investment was made.

Overall, the filing reflects routine equity-compensation vesting and related tax withholding rather than a discretionary buy or sell decision. Market impact is expected to be neutral barring other catalysts.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle performance del 16 marzo 2023. Per coprire le tasse di ritenuta, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo la vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un aumento di circa 132.000 azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “A” indica l'acquisizione da premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una negoziazione sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in contanti per l'interno; solo la vendita per la ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull'allineamento: L'esecutivo mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l'allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In sintesi, la segnalazione riflette un normale consolidamento di compensi azionari e relative ritenute fiscali piuttosto che una decisione discrezionale di acquisto o vendita. L'impatto sul mercato è previsto neutrale salvo altri catalizzatori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, identificada como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso adquirió 217,523 acciones Clase A mediante el último tramo de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a 2.79$ cada una. Tras la venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132,000 acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “A” indica adquisición por premio de capital; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta para retención fiscal tiene precio de mercado.
  • Impacto en alineación: La ejecutiva mantiene una participación accionaria considerable (≈3.3 millones de acciones), reforzando la alineación de incentivos, pero no se realizó ninguna inversión en efectivo nueva.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y retención fiscal relacionada, más que una decisión discrecional de compra o venta. Se espera que el impacto en el mercado sea neutral salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)는 “CEO, Medicare Advantage”로 등재된 Jamie L. Reynoso의 내부자 활동을 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 수여의 마지막 분할로 217,523 클래스 A 주식을 획득했습니다. 원천징수세를 충당하기 위해 회사는 자동으로 85,596주를 주당 2.79달러에 매도했습니다. 자동 매도 후 Reynoso 씨의 직접 보유 주식은 3,328,328 클래스 A 주식으로 이전 잔액보다 약 13만 2천 주 증가했습니다.

  • 거래 성격: “A” 코드는 주식 수여에 따른 취득을, “F” 코드는 세금 원천징수를 위한 주식 보유를 의미하며, 둘 다 공개 시장 거래를 나타내지 않습니다.
  • 원가 기준: RSU는 내부자가 현금 비용 없이 정산되었으며, 세금 원천징수 매도만 시장 가격이 반영되었습니다.
  • 정렬 영향: 경영진은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화했으나, 새로운 현금 투자는 이루어지지 않았습니다.

전반적으로 이번 제출은 임의 매수 또는 매도 결정이 아닌 정기적인 주식 보상 취득 및 세금 원천징수를 반영합니다. 다른 촉매가 없다면 시장 영향은 중립적일 것으로 예상됩니다.

Résumé du dépôt du Formulaire 4 : Clover Health Investments (CLOV) a rapporté une activité d'initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de Classe A via la dernière tranche d'une attribution de RSU basée sur la performance datée du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s'élève à 3 328 328 actions de Classe A, soit une augmentation d'environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition liée à une attribution d’actions ; le code « F » correspond aux actions retenues pour impôts — aucune des deux ne représente une transaction sur le marché libre.
  • Coût de base : Les RSU ont été attribuées sans coût en numéraire pour l’initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en numéraire n’a été réalisé.

Dans l’ensemble, ce dépôt reflète un vesting de compensation en actions de routine et la retenue fiscale associée plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu comme neutre, sauf autres catalyseurs.

Übersicht zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was einem Anstieg von etwa 132.000 Aktien gegenüber dem vorherigen Bestand entspricht.

  • Art der Transaktion: Code „A“ steht für Erwerb aus Aktienzuteilung; Code „F“ für einbehaltene Aktien zur Steuerabführung – keine der beiden stellt einen Handel am freien Markt dar.
  • Kostenbasis: Die RSUs wurden ohne Baraufwand für den Insider abgewickelt; nur der steuerbedingte Verkauf erfolgte zum Marktpreis.
  • Auswirkung auf Ausrichtung: Die Führungskraft hält weiterhin eine erhebliche Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizsetzung stärkt, jedoch wurde kein neues Barinvestment getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Aktienvergütung und zugehörige Steuerabführung wider, keine freiwillige Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser vorliegen.

Positive
  • Executive ownership rises by ~132,000 shares, increasing alignment with shareholders.
  • Performance-based vesting suggests the company met or exceeded predefined targets tied to the 2023 RSU grant.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting—neutral impact; insider’s stake increases, no open-market buying.

The 217.5 k share addition arises from a scheduled performance-based RSU vesting. The automatic 85.6 k-share sale merely covers payroll taxes. Net beneficial ownership growth of ~132 k shares (≈4 % of her prior holdings) is not large enough to signal a strong incremental vote of confidence, but it modestly enhances alignment. Because there is no discretionary purchase or sale, I view the filing as informational, not directional. Trading volume impact should be minimal.

TL;DR: Performance-based vesting confirms compensation plan progression; governance concerns minimal.

The disclosure shows Clover Health’s incentive structure functioning as designed: shares vest only after performance hurdles, with automatic tax withholding to avoid insider liquidity strain. The executive’s continued sizable ownership (3.3 M shares) exceeds common ownership guidelines, fostering shareholder alignment. There are no indications of problematic timing, 10b5-1 usage, or unusual dispositions. Therefore, the governance signal is neutral-to-slightly-positive, but not materially impactful to valuation.

Panoramica della segnalazione Form 4: Clover Health Investments (CLOV) ha riportato un'attività interna da parte di Jamie L. Reynoso, indicata come “CEO, Medicare Advantage.” Il 30 giugno 2025 la Sig.ra Reynoso ha acquisito 217.523 azioni di Classe A tramite l'ultima tranche di un premio RSU basato sulle performance del 16 marzo 2023. Per coprire le tasse di ritenuta, la società ha venduto automaticamente 85.596 azioni a 2,79$ ciascuna. Dopo la vendita automatica, la proprietà diretta della Sig.ra Reynoso ammonta a 3.328.328 azioni di Classe A, con un aumento di circa 132.000 azioni rispetto al saldo precedente.

  • Natura della transazione: Il codice “A” indica l'acquisizione da premio azionario; il codice “F” indica azioni trattenute per tasse—nessuno dei due rappresenta una negoziazione sul mercato aperto.
  • Base di costo: Le RSU sono state assegnate senza alcun costo in contanti per l'interno; solo la vendita per la ritenuta fiscale ha un prezzo di mercato.
  • Impatto sull'allineamento: L'esecutivo mantiene una consistente partecipazione azionaria (circa 3,3 milioni di azioni), rafforzando l'allineamento degli incentivi, ma non è stato effettuato alcun nuovo investimento in contanti.

In sintesi, la segnalazione riflette un normale consolidamento di compensi azionari e relative ritenute fiscali piuttosto che una decisione discrezionale di acquisto o vendita. L'impatto sul mercato è previsto neutrale salvo altri catalizzatori.

Resumen de la presentación del Formulario 4: Clover Health Investments (CLOV) reportó actividad interna por parte de Jamie L. Reynoso, identificada como “CEO, Medicare Advantage.” El 30 de junio de 2025, la Sra. Reynoso adquirió 217,523 acciones Clase A mediante el último tramo de una concesión de RSU basada en desempeño del 16 de marzo de 2023. Para cubrir impuestos retenidos, la empresa vendió automáticamente 85,596 acciones a 2.79$ cada una. Tras la venta automática, la propiedad directa de la Sra. Reynoso es de 3,328,328 acciones Clase A, un aumento de aproximadamente 132,000 acciones respecto al saldo anterior.

  • Naturaleza de la transacción: El código “A” indica adquisición por premio de capital; el código “F” indica acciones retenidas para impuestos—ninguno representa una operación en mercado abierto.
  • Base de costo: Las RSU se liquidaron sin costo en efectivo para el insider; solo la venta para retención fiscal tiene precio de mercado.
  • Impacto en alineación: La ejecutiva mantiene una participación accionaria considerable (≈3.3 millones de acciones), reforzando la alineación de incentivos, pero no se realizó ninguna inversión en efectivo nueva.

En general, la presentación refleja la consolidación rutinaria de compensación en acciones y retención fiscal relacionada, más que una decisión discrecional de compra o venta. Se espera que el impacto en el mercado sea neutral salvo otros catalizadores.

Form 4 제출 개요: Clover Health Investments (CLOV)는 “CEO, Medicare Advantage”로 등재된 Jamie L. Reynoso의 내부자 활동을 보고했습니다. 2025년 6월 30일, Reynoso 씨는 2023년 3월 16일 성과 기반 RSU 수여의 마지막 분할로 217,523 클래스 A 주식을 획득했습니다. 원천징수세를 충당하기 위해 회사는 자동으로 85,596주를 주당 2.79달러에 매도했습니다. 자동 매도 후 Reynoso 씨의 직접 보유 주식은 3,328,328 클래스 A 주식으로 이전 잔액보다 약 13만 2천 주 증가했습니다.

  • 거래 성격: “A” 코드는 주식 수여에 따른 취득을, “F” 코드는 세금 원천징수를 위한 주식 보유를 의미하며, 둘 다 공개 시장 거래를 나타내지 않습니다.
  • 원가 기준: RSU는 내부자가 현금 비용 없이 정산되었으며, 세금 원천징수 매도만 시장 가격이 반영되었습니다.
  • 정렬 영향: 경영진은 상당한 지분(약 330만 주)을 유지하여 인센티브 정렬을 강화했으나, 새로운 현금 투자는 이루어지지 않았습니다.

전반적으로 이번 제출은 임의 매수 또는 매도 결정이 아닌 정기적인 주식 보상 취득 및 세금 원천징수를 반영합니다. 다른 촉매가 없다면 시장 영향은 중립적일 것으로 예상됩니다.

Résumé du dépôt du Formulaire 4 : Clover Health Investments (CLOV) a rapporté une activité d'initié par Jamie L. Reynoso, désignée comme « CEO, Medicare Advantage ». Le 30 juin 2025, Mme Reynoso a acquis 217 523 actions de Classe A via la dernière tranche d'une attribution de RSU basée sur la performance datée du 16 mars 2023. Pour couvrir les retenues fiscales, la société a automatiquement vendu 85 596 actions à 2,79 $ chacune. Après cette vente automatique, la détention directe de Mme Reynoso s'élève à 3 328 328 actions de Classe A, soit une augmentation d'environ 132 000 actions par rapport au solde précédent.

  • Nature de la transaction : Le code « A » désigne une acquisition liée à une attribution d’actions ; le code « F » correspond aux actions retenues pour impôts — aucune des deux ne représente une transaction sur le marché libre.
  • Coût de base : Les RSU ont été attribuées sans coût en numéraire pour l’initié ; seule la vente liée à la retenue fiscale a un prix de marché.
  • Impact sur l’alignement : La dirigeante conserve une participation importante (environ 3,3 millions d’actions), renforçant l’alignement des incitations, mais aucun nouvel investissement en numéraire n’a été réalisé.

Dans l’ensemble, ce dépôt reflète un vesting de compensation en actions de routine et la retenue fiscale associée plutôt qu’une décision discrétionnaire d’achat ou de vente. L’impact sur le marché est attendu comme neutre, sauf autres catalyseurs.

Übersicht zur Form 4 Einreichung: Clover Health Investments (CLOV) meldete Insideraktivitäten von Jamie L. Reynoso, aufgeführt als „CEO, Medicare Advantage.“ Am 30. Juni 2025 erhielt Frau Reynoso 217.523 Class A Aktien durch die letzte Tranche einer leistungsabhängigen RSU-Zuteilung vom 16. März 2023. Zur Begleichung der Quellensteuer verkaufte das Unternehmen automatisch 85.596 Aktien zu je 2,79 $. Nach dem automatischen Verkauf hält Frau Reynoso direkt 3.328.328 Class A Aktien, was einem Anstieg von etwa 132.000 Aktien gegenüber dem vorherigen Bestand entspricht.

  • Art der Transaktion: Code „A“ steht für Erwerb aus Aktienzuteilung; Code „F“ für einbehaltene Aktien zur Steuerabführung – keine der beiden stellt einen Handel am freien Markt dar.
  • Kostenbasis: Die RSUs wurden ohne Baraufwand für den Insider abgewickelt; nur der steuerbedingte Verkauf erfolgte zum Marktpreis.
  • Auswirkung auf Ausrichtung: Die Führungskraft hält weiterhin eine erhebliche Beteiligung (ca. 3,3 Millionen Aktien), was die Anreizsetzung stärkt, jedoch wurde kein neues Barinvestment getätigt.

Insgesamt spiegelt die Meldung eine routinemäßige Aktienvergütung und zugehörige Steuerabführung wider, keine freiwillige Kauf- oder Verkaufsentscheidung. Die Marktauswirkung wird neutral erwartet, sofern keine weiteren Auslöser vorliegen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
OCAMPO SUSAN

(Last) (First) (Middle)
C/O MACOM TECHNOLOGY SOLUTIONS HOLDINGS
100 CHELMSFORD STREET

(Street)
LOWELL MA 01851

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MACOM Technology Solutions Holdings, Inc. [ MTSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 G(1) 200,000 D $0(1) 4,415,331 I By Ocampo Family Trust(2)
Common Stock 4,118,621(3) I By trusts for children(2)
Common Stock 1,500,000 I By GRAT(2)
Common Stock 1,623 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents a bona fide gift of shares to a charitable donor-advised fund in which the Reporting Person has no pecuniary interest.
2. The Reporting Person is a trustee of the Ocampo Family Trust, the GRAT and each of the following six trusts for the benefit of her children: (i) two trusts for her son; (ii) two trusts for her daughter; and (iii) two trusts for her son.
3. 1,124,543 of such shares are held by two trusts for the Reporting Person's son; 1,497,039 of such shares are held by two trusts for the Reporting Person's daughter; and 1,497,039 of such shares are held by two trusts for the Reporting Person's son.
/s/ Ambra R. Roth, Attorney-in-Fact 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Jamie L. Reynoso report for CLOV?

217,523 RSUs vested and 85,596 shares were withheld for taxes on 30 June 2025.

How many Clover Health shares does Reynoso own after the Form 4 filing?

She now directly owns 3,328,328 Class A shares.

Were any open-market purchases or sales involved?

No. The acquisition came from RSU vesting; the share sale was automatic tax withholding, not discretionary trading.

At what price were shares sold to cover taxes?

Shares were sold at $2.79 per share.

Does the filing indicate use of a Rule 10b5-1 plan?

No Rule 10b5-1 box is marked; the sale was automatic for tax withholding.
Macom Tech Solutions Hldgs Inc

NASDAQ:MTSI

MTSI Rankings

MTSI Latest News

MTSI Latest SEC Filings

MTSI Stock Data

10.58B
63.21M
16.24%
85.63%
2.61%
Semiconductors
Semiconductors & Related Devices
Link
United States
LOWELL